表达水疱性口炎病毒G基因重组新城疫病毒的构建及免疫原性研究

Construction of a recombinant Newcastle disease virus expressing vesicular stomatitis virus glycoprotein and evaluation of its immunogenicity

水疱性口炎是由水疱性口炎病毒（VSV）引起的人兽共患性传染病，在我国尚无可用疫苗。为研制安全有效的水疱性口炎疫苗，本研究以新城疫病毒（NDV）LaSota弱毒疫苗株反向遗传操作系统为基础，构建并拯救出表达VSV糖蛋白（GP）的重组病毒（rLa-VSV-G）。间接免疫荧光、激光共聚焦、western blot等试验证明VSV-GP在重组病毒中正确表达；体外致病试验结果表明，rLa-VSV-G保持了LaSota亲本株的低致病性和高滴度的鸡胚生长特性；rLa-VSV-G接种4周龄～5周龄BALB／c雌性小鼠后，可以诱导显著的VSV中和抗体反应。本研究表明，重组病毒rLa-VSV—G具有作为防控VSV储备性疫苗的潜力。

Vesicular stomatitis viruse （VSV） is the causative agents of vesicular stomatitis （VS）, a severe form of zoonotic infectious viral disease. In order to develop a safe and effective vaccine against VS, we constructed and rescued a recombinant Newcastle disease virus （NDV） of rLa-VSV-G which expressed VSV glycoprotein （VSV-GP） based on the reverse genetics system of NDV LaSota vaccine strain. The expression of VSV-GP from recombinant virus was confirmed by the immunofluorescence confocal microscopic assay and western blot. In addition, the rLa-VSV-G retained high-titer growth property and low pathogenicity in embryonated chicken egg as the parental virus of LaSota strain. Moreover, the rLa-VSV-G induced high titer of neutralizing antibodies against VSV in rLa-VSV-G inoculated mice. Our study shows that the rLa-VSV-G has the potential to be of a vaccine candidate against VSV infection.